HDAC8 and heart failure: This study demonstrated that pharmacological inhibition or downregulation of Hdac8 mitigates heart failure-related pathologies, including cardiac hypertrophy, pulmonary congestion, fibrosis, and inflammation in vivo (TAC-induced heart failure mouse model) and in vitro.